Preference of insomniac patients between a single dose of zolpidem 10 mg versus zaleplon 10 mg

Human Psychopharmacology

Volumn 18, Issue 5, 2003, Pages 369-374

  Allain, Hervé ^a   Bentué Ferrer, Danièle ^a   Le Breton, Stéphanie ^b   Polard, Elisabeth ^c   Gandon, Jean Marc ^b  

^a UNIVERSITÉ DE RENNES 1   (France)

^b Biotrial SA   (France)

^c RENNES UNIVERSITY HOSPITAL   (France)

Author keywords

Insomnia; Patient's preference; Sleep disorders; Zaleplon; Zolpidem

Indexed keywords

ANALGESIC AGENT; ZALEPLON; ZOLPIDEM TARTRATE;

ABDOMINAL DISEASE; ADULT; ARTICLE; CIRCADIAN RHYTHM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FEMALE; GENERAL PRACTITIONER; HEADACHE; HUMAN; INSOMNIA; LEG DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MEDICAL DECISION MAKING; MEDICAL INFORMATION; MENTAL CONCENTRATION; MENTAL DISEASE; NIGHT; NIGHT SLEEP; PATIENT ATTITUDE; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY CONTROL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SELF EVALUATION; SINGLE DRUG DOSE; SLEEP TIME; TONGUE DISEASE; TREATMENT OUTCOME; VERTIGO; VISUAL ANALOG SCALE; WAKEFULNESS;

ACETAMIDES; AGED; CIRCADIAN RHYTHM; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; MALE; MIDDLE AGED; PATIENT SATISFACTION; PYRIDINES; PYRIMIDINES; SLEEP; SLEEP INITIATION AND MAINTENANCE DISORDERS;

EID: 0041311013     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/hup.500     Document Type: Article

References (31)

1. Allain H, Arbus L, Schück S and the Zolpidem Study Group. 2001. Efficacy and safety of zolpidem administered 'as needed' in primary insomnia; results of a double blind, placebo controlled study. Clin Drug Invest 21: 391-400.
2. Allain H, Patat A, Lieury A, et al. 1995. Comparative study of the effects of zopiclone, zolpidem, flunitrazepam and a placebo on nocturnal cognitive performance in healthy subjects, in relation to pharmacokinetics. Eur Psychiatry 10(Suppl. 3): 129S-135S.
3. Bliven BD, Green CP, Spertus JA. 1998. Review of available instruments and methods for assessing quality of life in anti-anginal trials. Drugs Aging 13: 311-320.
4. Bocca ML, Le Doze F, Etard O, Pottier M, L'Hoste J, Denise P. 1999. Residual effects of zolpidem 10 mg and zopiclone 7.5 mg versus flunitrazepam 1 mg and placebo on driving performance and ocular saccades. Psychopharmacology 143: 373-379.
5. Bourin M, Malinge M. 1996. A new design of trial for hypnotic comparison: a double-blind cross-over trial with patient's preference assessment and continuation of the preferred treatment. Prog Neuro-Psychopharmacol Biol Psychiat 20: 373-385.
6. Chevalier H, Los F, Boichut D, et al. 1999. Evaluation of severe insomnia in the general population: results of a European multinational survey. J Psychopharmacol 13(4 Suppl. 1): S21-S24.
7. Danjou P, Paty I, Frincillo R, et al. 1999. A comparison of the residual effects of zaleplon and zolpidem following administration 5 to 2 h before awakening. Br J Clin Pharmacol 48: 367-374.
8. Danjou P, Puech A, Warot W, Benoit JF. 1987. Lack of sleep-inducing properties of propranolol (80 mg) in chronic insomniacs previously treated by common hypnotic medications. Int Clin Psychopharmacol 2: 135-140.
9. Doghramji PP. 2001. Treatment of insomnia with zaleplon, a novel sleep medication. Int J Clin Pract 55: 329-334.
10. Dooley M, Plosker GL. 2000. Zaleplon. A review of its use in the treatment of insomnia. Drugs 60: 413-445.
11. Drover D, Lemmens H, Naidu S, Cevalllos W, Darwish M, Stanski D. 2000. Pharmacokinetics, pharmacodynamics, and relative pharmacokinetic/pharmacodynamic profiles of zaleplon and zolpidem. Clin Ther 22: 1443-1461.
12. Elie R, Rüther E, Farr I, Emilien G, Salinas E. 1999. Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic. J Clin Psychiatry 60: 536-544.
13. Eschwège E, Bouvenot G. 1994. Essais explicatifs ou pragmatiques, le dualisme. Rev Med Interne 15: 357-361.
14. Everitt DE, Avorn J, Baker MW. 1990. Clinical decision-making in the evaluation and treatment of insomnia. Am J Med 89: 357-362.
15. Fairweather DB, Kerr JS, Hindmarch I. 1992. The effects of acute and repeated doses of zolpidem on subjective sleep, psychomotor performance and cognitive function in elderly volunteers. Eur J Clin Pharmacol 43: 597-601.
16. Hajak G, Bandelow B, Pittrow D, Zulley J. 2002. ;As needed' zolpidem pharmacotherapy complemented by stimulus control treatment in chronic insomnia - assessment of a novel intervention strategy in a primary care setting. Ann Clin Psychiatry 14: 1-7.
17. Holm KJ, Goa KL. 2002. Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia. Drugs 59: 865-889.
18. Laska EM, Klein DF, Lavori PW, et al. 1994. Design issues for the clinical evaluation of psychotropic drugs. In Clinical Evaluation of Psychotropic Drugs: Principles and Guidelines, Prien RF, Robinson DS (eds). Raven Press: New York; 29-67.
19. Parrott AC, Hindmarch I. 1980. The Leeds sleep evaluation questionnaire in psychological investigations - a review. Psychopharmacology 71: 73-179.
20. Patrick DL, Chiang YP. 2000. Measurement of health outcomes in treatment effectiveness evaluations: conceptual and methodological challenges. Med Care 38(9 Suppl.): 14-25.
21. Rosen AS, Fournié P, Darwish M, Danjou P, Troy SM. 1999. Zaleplon pharmacokinetics and absolute bioavailability. Biopharm Drug Dispos 20: 171-175.
22. Sanger DJ, Morel E, Perrault G. 1996. Comparison of pharmacological profiles of the hypnotic drugs, zaleplon and zolpidem. Eur J Pharmacol 313: 35-42.
23. Soyka M, Bottlender R, Moller HJ. 2000. Epidemiological evidence for a low abuse potential of zolpidem. Pharmacopsychiatry 33: 138-141.
24. Troy SM, Lucki I, Unruh MA, et al. 2000. Comparison of the effects of zaleplon, zolpidem, and triazolam on memory, learning, and psychomotor performances. J Clin Psychopharmacol 20: 328-337.
25. Vermeeren A, Danjou PE, O'Hanlon JF. 1998. Residual effects of evening and middle-of-the-night administration of zaleplon 10 and 20 mg on memory and actual driving performance. Hum Psychopharmacol Clin Exp 13: S98-S107.
26. Vermeeren A, O'Hanlon JF, Declerck AC, et al. 1995. Acute effects of zolpidem and flunitrazepam on sleep, memory and driving performance, compared to those of partial sleep deprivation and placebo. Acta Ther 21: 47-64.
27. Walsh JK, Pollak CP, Scharf MB, Schweitzer PK, Vogel GW. 2000. Lack of residual sedation following middle-of-the-night zaleplon administration in sleep maintenance insomnia. Clin Neuropharmacol 23: 17-21.
28. Ward MM, Marx AS, Barry NN. 2000. The rating scale preference measure as an evaluative measure in systemic lupus erythematosus. Lupus 9: 696-701.
29. Weitzel KW, Wickman JM, Augustin SG, Strom GS. 2000. Zaleplon: a pyrazolopyrimidine sedative-hypnotic agent for the treatment of insomnia. Clin Ther 22: 1254-1267.
30. Wilkinson CJ. 1995. The acute effects of zolpidem, administered alone and with alcohol, on cognitive and psychomotor function. J Clin Psychiatry 56: 309-318.
31. Wittchen HU, Krause P, Höfler M, et al. 2001. NISAS-2000: Die 'Nationwide Insomnia Screening and Awareness Study'. Insomnien und Schlafstörungen in der allgemeinärztlichen Versorgung. Nervenheilkunde 20: 4-16.